Premium
Toward Greater Insights on Pharmacokinetics and Exposure–Response Relationships for Therapeutic Biologics in Oncology Drug Development
Author(s) -
Wang Y,
Booth B,
Rahman A,
Kim G,
Huang SM,
Zineh I
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.628
Subject(s) - dosing , medicine , pharmacokinetics , drug , therapeutic drug monitoring , oncology , drug development , pharmacology , regimen , intensive care medicine
There has been increased interest in optimizing dosing regimens for oncology products over the past decade. Investigations to refine dosing regimens often occur after new drug approval.[1][Wang, Y., ] There is growing focus on the use of exposure–response (ER) approaches to identify optimal dosing regimens for therapeutic biologics. Herein, we describe several recent observations that have informed our thinking on the use of ER analyses in the dose regimen optimization of therapeutic biologics developed to treat cancer.